Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Glaxo holds its breath
A late-stage hit with its respiratory syncytial virus jab would be a huge validation for the group’s new focus.
Nirsevimab data leave the door open for Pfizer
A lack of impact on hospitalisations could hit Astra and Sanofi’s plans for broad use.
